<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700618</url>
  </required_header>
  <id_info>
    <org_study_id>PPV23-2021-2</org_study_id>
    <nct_id>NCT04700618</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old</brief_title>
  <official_title>A Phase Ⅳ Clinical Trial to Evaluate the Safety and Immunogenicity of 23 Valent Pneumococcal Polysaccharide Vaccine Revaccinated in 60-70 Years Old in Shanghai</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Municipal Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the safety and immunogenicity of PPV23 vaccine revaccinated in 60-70&#xD;
      years old in Shanghai.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Antibody double growth rate in 28-40 days after immunization;&#xD;
&#xD;
        2. Antibody GMC level in 28-40days after immunization;&#xD;
&#xD;
        3. Incidence of adverse reactions in 0-30days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study group is PPV23 revaccination and control group PPV23-vaccination.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody doubling rate</measure>
    <time_frame>The blood collection time was 28-40 days after vaccination.</time_frame>
    <description>The difference of serum antibody double growth level between the two groups was compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody GMC level</measure>
    <time_frame>The blood collection time was 28-40 days after vaccination.</time_frame>
    <description>The difference of serum antibody GMC level between the two groups was compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse reactions</measure>
    <time_frame>Within 30 days after vaccination.</time_frame>
    <description>Adverse reactions were collected during the observation period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Vaccination</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in the study group had been vaccinated with 23 valent pneumococcal polysaccharide vaccine made in China for more than 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group had never been vaccinated with any pneumococcal vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent pneumococcal polysaccharide vaccine</intervention_name>
    <description>The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The age was 60-70 years old on the day of enrollment;&#xD;
&#xD;
          2. The subjects have signed the informed consent and signed the date;&#xD;
&#xD;
          3. The subjects are able to participate in all planned follow-up visits and were able to&#xD;
             follow all trial procedures (e.g. complete diary card / contact card, return to&#xD;
             visit);&#xD;
&#xD;
          4. The subjects in the study group had been vaccinated with 23 valent pneumococcal&#xD;
             polysaccharide vaccine made in China for more than 5 years;&#xD;
&#xD;
          5. The control group had never been vaccinated with any pneumococcal vaccine; 6.Axillary&#xD;
             temperature ≤37.0℃.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathia and&#xD;
             neurological illness;&#xD;
&#xD;
          2. Allergic to any ingredient of vaccine or with allergy history to any vaccine;&#xD;
             3.Subjects with immunodeficency or suspected impairment of immunologic function (e.g.&#xD;
             caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking&#xD;
             orally injecting of steroid hormone);&#xD;
&#xD;
        4.Administration of immunoglobulins within 30 days prior to this study; 5.Acute febrile&#xD;
        disease(temperature ≥ 37.0°C) or infectious disease; 6.With a clearly diagnosed history of&#xD;
        thrombocytopenia or other coagulopathy, may cause contraindications for subcutaneous&#xD;
        injection; 7.With any serious chronic illness, acute infectious diseases, or respiratory&#xD;
        diseases; 8.Suffering from serious cardiovascular diseases (pulmonary heart disease,&#xD;
        pulmonary edema, hypertension can not be controlled to normal by drugs), liver and kidney&#xD;
        diseases, diabetes with complications; 9.With any kind of infectious, purulent, or allergic&#xD;
        skin diseases; 10.With any other factor that makes the investigator determines the subject&#xD;
        is unsuitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Guo</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Municipal Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Zhang</last_name>
    <phone>+8613381185218</phone>
    <email>zhangmin26@sinopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai municipal center for disease control and prevention</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Guo</last_name>
      <phone>+8613818010874</phone>
      <email>guoxiang@scdc.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

